These patient vignettes, based on the experiences of real participants in the Michigan Oncology Sequencing Center (MI-ONCOSEQ) DNA sequencing study, help adults understand what to expect should they choose to participate in the study and receive or choose not to receive certain study results.

This published study protocol for the MedSeq trials includes a description of the study design; recruitment, enrollment, and sample size plan; patient exclusion/inclusion criteria; and process of interpreting WGS results and delivering them to physicians. It also includes an example of a general genome report as well as a cardiac risk report.

This document is the study protocol of the Institutional and Professional Impact of Genomic Sequencing in Cancer Care study. Appendices include the following: Email Notification to Oncologists about Study Implementation Information Sessions, Email Invitation to Oncologists to Participate in Cognitive Testing, Email Invitation to Attend an Initial Clinical Genomics Evaluation Committee Meeting, Physician Baseline Survey, Email Notification to Oncologists to Complete the Baseline Survey, Follow up Email Notification to Oncologists to Complete the Baseline Survey, New Physician Post-disclosure Survey – Informative Results, Old Physician Post-disclosure Survey, Physician Post-Disclosure Survey – Uninformative Results, Email Notification to Oncologists to Complete the Post-disclosure Survey, Reminder Email Notification to Oncologists to Complete the Post-disclosure Survey, Email Invitation for the Baseline Qualitative Interview, and Email Invitation for the One-Year Follow up Qualitative Interview.

This document is the Use of Sequencing to Guide the Care of Cancer Patients study protocol. Appendices include the following: Measures for Patient Baseline, Email Notification to Patients to Complete Baseline Survey, Measures for Patient Post-Disclosure Survey in the Setting of Uninformative Sequencing Results, Measures for Patient Post-Disclosure Survey in the Setting of Informative Sequencing Results, Training plan for CRCs, Patient Baseline Reminder Letter, Patient Post-Disclosure Email Invitation and reminder email, Patient Post-Disclosure Reminder invitation and reminder letter, CanSeq Patient Informed Consent Interview Guide, Patient Information brochure, Post-Disclosure email introduction, ACMG Guidelines, Patient Preferences Communication, Gift Card Thank You Letter, and Patient Post-Disclosure Interview.

The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.

The Personalized Medicine Based on Molecular Profiling of Patients with Cancer implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.

Genomics ADvISER is a digital decision aid for use in the delivery of genomic counseling. It is intended as a supplement to genomic counseling with a counselor. Genomics ADvISER guides users through a ten-minute video of basic genomic sequencing concepts and five categories of secondary findings followed by brief interactive questionnaires about values, knowledge, and decision-making needs. Please contact the authors of the study to use this tool.

The Optional Results Choice Aid (ORCA) is a decision aid to support informed, values based decision-making for adult patients and research participants about the reciept of medically actionable, additional findings from genomic sequencing. ORCA will be implemented and evaluated in the NHGRI-funded Cancer Health Assessment Reaching Many (CHARM) study.

This plain text script includes descriptions of the three animated videos that were utilized in the ROMP study, which assessed adult patient's attitudes toward research on medical practices in the context of usual care.

The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.